Axicabtagene Ciloleucel

HONG KONG, Dec. 17, 2024 /PRNewswire/ -- On 13 December 2024, the "TVB ESG Awards" ceremony, hosted by Television Broadcasts Limited (hereinafter referred to as "TVB"), was held at the Hong Kong Convention and Exhibition Centre. Fosun International was honored with the highest accolade, the "Outstanding ESG Award", as well as awards for "Best in ESG Practices" and "Best in ESG Report". Officiating guests at the awards ceremony included Mr. Wong Wai Lun, Michael, GBS, JP, Deputy Financial Secretary of the Government of the Hong Kong Special Administrative Region (SAR), Mr. Chan Ho Lim, Joseph, JP, Under Secretary for Financial Services and the Treasury of the Government of the Hong Kong SAR, Mr. Wong Chuen Fai, JP, Commissioner for Climate Change, Environment and Ecology Bureau of the Government of the Hong Kong SAR, and Mr. Siu Sai Wo, General Manager (Business Operations) of TVB, who jointly presented the "Outstanding ESG Award" to Fosun International. TVB pointed out that Fosun International's recognition with the "Outstanding ESG Award", "Best in ESG Practices" and "Best in ESG Report" is well-deserved. After 30 years of development, Fosun has developed into a large globalized company with operations spanning healthcare, tourism, consumption, and insurance. With a robust global industrial ecosystem, Fosun operates responsibly in over 35 countries and regions, actively contributing to public welfare and creating sustainable value worldwide. Looking back on the past, Fosun has always paid attention to the reform and development of the global policies in the field of sustainable development. It has established a comprehensive ESG management system, integrated ESG management requirements into business management over the years, actively responded to national and global strategies in relation to sustainable development, ensured information security, promoted technology innovation, implemented "dual carbon" goals, protected the rights and interests of employees to promote sustainable management and value creation. This year, a total of five organizations received the prestigious "Outstanding ESG Award" from TVB, all of which have demonstrated excellence in ESG. These include government agency, major public utility, and well-known enterprises: the Drainage Services Department of the Government of the Hong Kong SAR, CLP Power Hong Kong Limited, Chinachem Group, and Crystal International Group. The companies awarded "Best in ESG Practices" and "Best in ESG Report" are all prominent firms in Hong Kong, including MTR Corporation, Henderson Land Development, Sino Land, and NWS Holdings. After accepting the "Outstanding ESG Award", Angel Sze, Company Secretary and Head of the ESG Management Committee of Fosun International, took part in a discussion with representatives from other award-winning organizations to share Fosun's ESG achievements. Actively giving back to society through innovation During the discussion, Angel Sze remarked, "Since its establishment, Fosun has remained dedicated to its original aspiration of 'Contribution to Society' and strives to create a positive impact through business. For instance, in our pharmaceutical business, we focus on technology innovation and have made significant breakthroughs in cancer treatment. The CAR-T cell therapy product Yi Kai Da (ejilunsai injection), developed by Fosun Kite, is the first CAR-T cell therapy approved for marketing in the Chinese mainland, bringing lymphoma patients more treatment options and hope for recovery." Thanks to the long-term accumulated technology innovation capabilities, Fosun has continued to realize the "world's first" and "China's first" achievements. Fosun Pharma's self-developed artesunate for injection saved more than 72 million patients with severe malaria around the world as of the first half of 2024. Its second-generation artesunate for injection (Argesun®) is the first injectable artesunate presented with a single solvent system to receive prequalification from the World Health Organization (WHO-PQ) for the treatment of malaria. Voluntarily releasing Climate Information Disclosures Report, calling for joint efforts towards carbon neutrality In 2021, Fosun made a commitment to society – "strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050". Fosun has formulated strategies for climate change mitigation and adaptation to align with the 1.5°C temperature control target set in the Paris Agreement. In order to achieve Fosun's carbon peaking and carbon neutrality goals, the Group has established a Carbon Neutrality Committee and a Carbon Neutrality Working Group to actively promote further implementation and enforcement of carbon-neutral management within the Group. In April this year, in the face of increasingly severe global climate change challenges, Fosun released its second Climate Information Disclosures Report with reference to the disclosure requirements of the Hong Kong Stock Exchange, the Task Force on Climate-Related Financial Disclosures (TCFD) recommendations and IFRS S2 Climate-related Disclosures, demonstrating its commitment of climate action to international community and calling on all sectors to jointly promote carbon neutrality. In terms of climate action, the Group and its member companies actively promote energy conservation and carbon reduction. Fidelidade, Fosun's insurance company in Portugal, has recently established the Impact Center For Climate Change (ICCC), a knowledge center dedicated to climate change research. Through collaborations with external entities, including universities, research centers, and public institutions, it provides scientific insights on the impacts of climate change on society, particularly in the insurance industry. In addition, The Group's Atlantis Sanya obtained the highest level of green building certification in China and other leading environmental certifications in the global tourism industry. The Bund Finance Center (BFC), Fosun's base in Shanghai and landmark in Shanghai, was awarded the LEED Platinum certification, which is hailed as the "Oscar Award" in the green building industry, with a score of 97 points to set a new world record. Fosun is committed to "globalization" and "innovation", striving to build a more responsible, inclusive and sustainable future This year, Fosun has formulated its sustainable development strategy: "Create IMPACT", which stands for I: Innovation-driven, M: Mindful Operation, P: People and Partner Oriented, A: Advanced Governance, C: Climate and Planet Positive and T: Transparency. This strategy continues Fosun's original aspiration of "Self-improvement, Teamwork, Performance and Contribution to Society", and serves as a foundation for long-term ESG practices. Rooted in China, Fosun has been developing globally and has long adhered to the two core growth drivers of "globalization" and "innovation". As one of the few Chinese companies with established global operational and investment capabilities, Fosun has cultivated profound expertise in technology and innovation. With an increasingly sophisticated global business presence, Fosun operates responsibly in more than 35 countries and regions, actively contributing to public welfare and creating sustainable value worldwide. Looking ahead, Fosun remains dedicated to advancing its social responsibility through innovation and responsible global operations. Guided by its "Create Impact" sustainable development strategy, Fosun will intensify its efforts to build a more responsible, inclusive and sustainable future. SOURCE Fosun WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Cell therapy developer Arcellx contends its lead program could be a safer alternative to currently available CAR T-treatments for multiple myeloma, noting that its previously reported preliminary data show the absence of worrisome neurological complications some fear could be associated with the broader therapeutic class. More detailed data presented at the American Society of Hematology annual meeting build on the safety profile of the Gilead Sciences-partnered Arcellx therapy, which some analysts now say has the potential to be best in its class. In a pivotal Phase 2 test of the Arcellx therapy, anitocabtagene autoleucel (anito-cel), 97% of patients responded to the one-time treatment. This study is evaluating anito-cel in patients who have had at least three prior lines of therapy. With a median follow-up of 9.5 months, 62% of patients achieved a complete response to anito-cel. On these efficacy measures, analysts say the results so far are comparable to Carvykti, the BCMA-targeting cell therapy marketed by Johnson & Johnson and Legend Biotech. But Arcellx could differentiate with better safety. One concern about Carvykti is the risk of parkinsonism, a movement disorder. In Carvykti’s clinical trials, parkinsonism was reported in 3% (eight of 285) of study participants. Five of those cases were classified as Grade 3 or higher. There was a delayed onset for this complication, which was observed weeks after administration of the therapy. The other available BCMA-targeting cell therapy is Abecma, from Bristol Myers Squibb and 2Seventy Bio. Sponsored Post The Funding Model for Cancer Innovation is Broken — We Can Fix It Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches. By Eve McDavid - CEO of Mission-Driven Tech In the more than 150 patients dosed with anito-cel, Arcellx said there are no cases of parkinsonism so far, nor are there any reports of cranial nerve palsies or Guillain-Barré syndrome, a condition in which the immune system damages nerve cells. For anito-cel, better safety is in the therapy’s design. Autologous cell therapies are made by harvesting a patient’s immune cells and engineering them to go after a target. Arcellx engineers its therapies with a synthetic binding domain it calls D-Domain. D-Domain enables high expression of the chimeric antigen receptor for the target protein, which in the case of anito-cel is BCMA. But this binder is engineered in a way that reduces the risk of sparking an immune response. Better safety was one of the features that drew the interest of Gilead. Two years ago, Gilead paid Arcellx $225 million up front and made a $100 million equity investment in the biotech, beginning an alliance on anito-cel (known in earlier stages of development as CART-ddBCMA). Depending on the program’s progress, Arcellx could earn up to $3.9 billion in milestone payments. If anito-cel is approved, the two companies will share in commercialization of the therapy. For William Blair analyst Sami Corwin, the lack of any delayed neurological events in clinical testing so far is a key point of differentiation for the Arcellx therapy. In a note sent to investors, she said that while there were high rates of an excessive immune response called cytokine release syndrome, this complication is consistent with the entire class of CAR T-therapies and was manageable. One hurdle for cell therapy is manufacturing, which happens in a multi-step process that can take a month or more. Arcellx says it can offer a 17-day turnaround time for anito-cel leveraging the manufacturing infrastructure Kite has developed for its commercialized cell therapies. A panel of physicians speaking at an Arcellx investor event Monday evening noted that the rapid turnaround time improves the overall experience of CAR T-therapy for patients and clinicians. Exclusive Heard at HLTH 2024: Insights from Innovative Healthcare Executives Executives from Imagine360, Verily, BrightInsight, Lantern, and Rhapsody shared their approaches to reducing healthcare costs and facilitating digital transformation. By MedCity News The process of turning a patient’s immune cells into a living drug isn’t always successful, but Arcellx said anito-cell was successfully manufactured for 99% of patients in its studies. Kite, which produces the FDA-approved cell therapies Yescarta and Tecartus, claims a 96% commercial manufacturing success rate with more than 25,000 patients treated by therapies produced from a CAR T infrastructure that has more than 500 authorized treatment centers globally, including 150 centers in the U.S. Corwin noted that the smaller size of the D-Domain means it is more readily expressed by the engineered cells, which should enable consistent manufacturing of the end product at commercial scale. “We think Kite’s reputation as a CAR T leader and established network of [authorized treatment centers] will lend itself to a strong commercial launch for anito-cel in 2026, if approved,” Corwin said. Like Corwin, Leerink Partners analyst Daina Graybosch believes anito-cel has best-in-class potential, for safety as well as the manufacturing advantages that Gilead’s Kite division brings. In a research note, she described Kite as “head and shoulders above the field when it comes to cell therapy manufacturing and operational excellence.” However, Arcellx’s manufacturing is currently done by contractors Lonza and Oxford Biomedica. Graybosch said there’s some uncertainty about whether Kite can complete the technology transfer for the therapy in a timely manner and whether the speed and quality of the manufacturing will translate to anito-cel, particularly as the Arcellx therapy uses a lentivirus for delivery while Kite’s current therapies employ a gamma retrovirus. Arcellx is currently enrolling patients in a Phase 3 test of anito-cel. This study will evaluate the cell therapy in patients who have received one to three prior lines of treatment for multiple myeloma. The Phase 3 study will employ Kite’s manufacturing capabilities, Arcellx said in an investor presentation. Illustration from Arcellx IPO prospectus